Amgen announced results from its Phase 3 studies of Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC). The first study demonstrated the addition of Vectibix to FOLFOX (an oxaliplatin-based chemotherapy) significantly improved Progression-Free Survival (PFS) (median 9.6 months for Vectibix plus FOLFOX versus 8 months for patients treated with FOLFOX alone, hazard ratio 0.80; 95% CI: 0.66-0.97; p=0.02) in the first-line treatment of patients with wild-type KRAS mCRC.  The second study demonstrated the addition of Vectibix to FOLFIRI (an irinotecan-based chemotherapy) significantly improved PFS (co-primary endpoint) (median 5.9 months for Vectibix plus FOLFIRI versus 3.9 months for patients treated with FOLFIRI alone, hazard ratio 0.73; 95% CI: 0.59-0.90; p=0.004) in the second-line treatment of patients with wild-type KRAS mCRC.

Vectibix is indicated as a single agent for the treatment of EGFR-expressing mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

For more information call (800) 772-6436 or visit www.vectibix.com.